Business

US Government Studying Allergic Reactions to COVID-19 Vaccine

National Institutes of Health said it started on Wednesday Clinical trial Moderna Inc. Evaluation of allergic response to the mRNA COVID-19 vaccine developed by.
MRNA,
-0.16%

And BioNTech SE
BNTX,
-2.36%

/Pfizer Japan Inc
PFE,
-0.10%
..
The goal is to understand who is at high risk, such as those with a history of allergic reactions or those diagnosed with mastocytosis. (Mast cells are part of the body’s immune system. Mutations in these cells can cause one of several rare disorders.) A number funded by the National Institute of Allergy and Infectious Diseases. The Phase 2 clinical trial enrolls 3,400 adults. Those who fall into one of three categories: Those who have previously reported a severe allergic reaction to food, insects, or drugs. Persons diagnosed with mastocytosis; or individuals with no history of either.Centers for Disease Control and Prevention To tell Anaphylaxis as a result of the COVID-19 vaccine occurs in up to 5 out of 1 million vaccinated people. These events “most often” occur within 30 minutes of receiving the shot.

US Government Studying Allergic Reactions to COVID-19 Vaccine

Source link US Government Studying Allergic Reactions to COVID-19 Vaccine

Back to top button